Skip to main content
Premium Trial:

Request an Annual Quote

GE Finalizes Acquisition of Certain Thermo Fisher Assets

NEW YORK (GenomeWeb News) — Thermo Fisher Scientific has completed the sale of certain assets to GE, the companies said today.

Specifically, GE acquired Thermo Fisher's HyClone cell culture media and sera, as well as its gene modulation and magnetic beads businesses, for $1.065 billion.

The businesses will become part of GE Healthcare's Life Sciences division, and will allow the company to expand its offering of tool, technologies, and services for the discovery and manufacture of new medicines, vaccines, and diagnostics, GE said.

The companies first announced the deal in January. In aggregate the three businesses generated approximately $250 million in revenues in 2013. Thermo Fisher said in November it would sell the business in order to expedite approval by the European Commission of the company's $13.6 billion acquisition of Life Technologies.

Thermo Fisher's acquisition of Life Tech was completed on Feb. 3, less than a week after the US Federal Trade Commission cleared the deal.

The Scan

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.

Meta AI Computer Model Rapidly Predicts Hundreds of Millions of Metagenomic Proteins

Meta AI researchers describe in Science a new large language model that can predict the structures of millions of metagenomic proteins.

Hutch Team Develops Platform for Assessing Impact of SARS-CoV-2 Spike Mutations

The approach described in Cell relies on lentiviral pseudotyping for mutational scanning, which the researchers applied to the SARS-CoV-2 spike protein.

Potential New Therapeutic Target for Rheumatoid Arthritis Discovered

Researchers report in the American Journal of Human Genetics that SNPs implicated in rheumatoid arthritis often regulate the expression of the inflammation-related SPRED2 gene.